26,309 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) during the 4th quarter, HoldingsChannel reports. The fund acquired 26,309 shares of the company’s stock, valued at approximately $192,000.

Several other large investors also recently bought and sold shares of VIR. Geode Capital Management LLC grew its stake in Vir Biotechnology by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company’s stock valued at $16,127,000 after acquiring an additional 7,827 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Vir Biotechnology by 58.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company’s stock valued at $14,059,000 after purchasing an additional 703,360 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Vir Biotechnology by 10.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company’s stock valued at $9,194,000 after purchasing an additional 118,379 shares during the last quarter. Renaissance Technologies LLC lifted its position in Vir Biotechnology by 4.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,237,600 shares of the company’s stock worth $9,084,000 after buying an additional 55,300 shares in the last quarter. Finally, Artisan Partners Limited Partnership acquired a new position in Vir Biotechnology during the fourth quarter worth $6,742,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Barclays lifted their price target on Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. Leerink Partners increased their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group lowered their price objective on Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $33.57.

Insiders Place Their Bets

In other Vir Biotechnology news, EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the sale, the executive vice president now owns 79,460 shares in the company, valued at $726,264.40. This represents a 8.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total value of $474,286.40. Following the completion of the transaction, the chief executive officer now owns 769,505 shares of the company’s stock, valued at $4,578,554.75. The trade was a 9.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 99,611 shares of company stock worth $663,525 over the last three months. Company insiders own 15.60% of the company’s stock.

Vir Biotechnology Stock Performance

NASDAQ:VIR opened at $5.09 on Friday. The stock has a market capitalization of $702.75 million, a P/E ratio of -1.30 and a beta of 1.36. Vir Biotechnology, Inc. has a fifty-two week low of $4.95 and a fifty-two week high of $14.45. The company has a 50 day moving average price of $6.28 and a 200 day moving average price of $7.93.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $3.03 million during the quarter, compared to analyst estimates of $8.59 million. During the same period in the previous year, the firm posted ($0.48) earnings per share. The company’s quarterly revenue was down 94.6% compared to the same quarter last year. Research analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).